LEE'S PHARM.
李 氏 大 藥 廠

Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)
(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT ENTERING INTO EXCLUSIVE LICENSE-OUT AND SUPPLY AGREEMENT WITH ASHLINS FOR INTERFERON ALPHA-2B PRODUCTS OUTSIDE GREATER CHINA

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Lee's Pharmaceutical Holdings Limited (the "**Company**" or "**Lee's Pharm**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board of the Company is pleased to announce that, on the 6 July 2026, the Company entered into an exclusive licensing agreement (the "**Agreement**") with Ashlins Ocular Pharmaceuticals, Inc. ("**Ashlins**"), a U.S.-based biopharmaceutical company and a wholly owned subsidiary of Ashlins Pharmaceuticals Holdings, Inc., focused on acquiring, developing and commercialising clinically validated therapies that address areas of significant unmet medical need. Pursuant to the Agreement, the Company has agreed to license and supply Interferon Alpha-2b to Ashlins for the development and commercialisation of drug products for the diagnosis, prevention, or treatment of certain human diseases in all territories other than Mainland China, Hong Kong, Macau and Taiwan (the "**Territory**"). The Company will receive an upfront payment and is eligible to receive additional development milestone and annual commercial milestone payments upon commercialisation based on specific achievements.

ABOUT INTERFERON ALPHA-2B

Interferon Alpha-2b is a recombinant human type I interferon active pharmaceutical ingredient produced by recombinant DNA technology and used as the active substance in medicinal products with antiviral and immunomodulatory activity.

* *For identification purpose only*

ABOUT ASHLINS

Ashlins is a U.S.-based biopharmaceutical company focused on acquiring, developing, and commercialising clinically validated therapies that address areas of significant unmet medical need. Ashlins' leadership team brings extensive experience in U.S. regulatory strategy, clinical development, FDA approval pathways, and commercialisation.

ABOUT LEE'S PHARM

The Company is a research-driven and market-oriented biopharmaceutical company with more than 30 years' experience in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with numerous international companies in the U.S., Europe, and Asia, and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key therapeutic areas such as cardiovascular health, woman's health, paediatrics, rare diseases, oncology, dermatology and obstetrics. In addition, the Company has recently acquired U.S.-based assets in line with its strategy to broaden its portfolio of innovative drug delivery technologies covering a wide range of indications and reinforcing the Company's global expansion strategy. More information is available at www.leespharm.com.

By order of the Board of
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 17 July 2026

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive directors of the Company, Dr. Li Xiaoyi, Mr. James Charles Gale and Mr. Huang Zuie-Chin are non-executive directors of the Company, and Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.